[Phase III studies of combined chemotherapy and radiation in locally advanced non-small-cell lung cancer and limited small-cell lung cancer].
Large phase III studies for lung cancer are reviewed. In an effort to improve survival results in locally advanced inoperable non-small-cell lung cancer (NSCLC), several studies have documented survival advantage for cisplatin + vinka alkaloid followed by radiotherapy (RT) when compared with RT alone. In SCLC, meta-analyses show that thoracic radiotherapy moderately improves survival in patients who are treated with combination chemotherapy. The optimum combination of chemotherapy and radiotherapy needs to be established.
Kawahara
M
M
Dept. of Internal Medicine, National for Chest Disease, Kinki Central Hospital.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D014748:Vinca Alkaloids / Q000008:administration & dosage
D014748:Vinca Alkaloids; D002945:Cisplatin